AIM ImmunoTech Inc. (AIM)

$0.7457

+0.00 (+0.50%)
Rating:
Recommendation:
-
Symbol AIM
Price $0.7457
Beta -0.462
Volume Avg. 0.16M
Market Cap 35.830M
Shares () -
52 Week Range 0.55-2.2
1y Target Est -
DCF Unlevered AIM DCF ->
DCF Levered AIM LDCF ->
ROE -33.20% Strong Sell
ROA -36.05% Strong Sell
Operating Margin -
Debt / Equity 4.31% Neutral
P/E -
P/B 0.73 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AIM news


Mr. Thomas Equels
Healthcare
Biotechnology
American Stock Exchange

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.